Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2050052 | FEBS Letters | 2008 | 6 Pages |
Abstract
Anti-VEGF treatment has become accepted first-line treatment for choroidal neovascularisation (CNV) in age-related macular degeneration. However, VEGF-inhibition does not always lead to sustained CNV-reduction. In this study, the effect of rapamycin was superior to VEGF-inhibition in a co-culture assay of endothelial cells (ECs) and retinal pigment epithelium (RPE). Rapamycin reduced EC sprouting in groups that did not respond to anti-VEGF treatment. Rapamycin did not induce EC apoptosis, but reduced both VEGF-production in RPE and the responsiveness of ECs to stimulation. Rapamycin might therefore be a therapeutic option for CNV patients that do not respond sufficiently to the established anti-VEGF treatments.
Related Topics
Life Sciences
Agricultural and Biological Sciences
Plant Science
Authors
A. Stahl, L. Paschek, G. Martin, N.J. Gross, N. Feltgen, L.L. Hansen, H.T. Agostini,